Boston Consulting Group (BCG) and Hippocratic AI have announced a global strategic collaboration to accelerate the responsible deployment of generative AI agents across the biopharmaceutical and medical technology industries. The partnership aims to move organizations beyond AI experimentation and into large-scale, real-world impact by combining Hippocratic AI’s safety-first, healthcare-specific AI technology with BCG’s strategic, operational, and AI transformation expertise. Despite growing investment in digital tools, BCG research shows that only a small fraction of biopharma and medtech companies are successfully generating sustainable value from AI. This collaboration is designed to close that gap by enabling clients to scale AI applications that deliver measurable business and patient outcomes. Hippocratic AI brings its advanced generative AI health care agents, built specifically for regulated clinical and life sciences environments. These non-diagnostic agents support a range of patient and operational tasks, including patient onboarding, treatment adherence, clinical trial coordination, and post-market follow-up. With over 150 million clinical interactions processed since 2023, the agents are powered by the company’s proprietary Polaris Constellation architecture, which ensures safety, accuracy, and consistent, empathetic performance in high-stakes healthcare settings. BCG contributes its deep experience in C-suite advisory, AI transformation, and commercial strategy. The firm’s Health Care Commercial AI by BCG X offering helps health care leaders modernize their commercial models, enhance omnichannel engagement, and achieve performance improvements. BCG X’s ongoing research, including benchmark studies and global roundtables, provides critical insights into AI adoption trends in life sciences. Ashkan Afhkami, BCG managing director and senior partner, and global leader for the Health Care practice at BCG X, said the partnership is about turning AI potential into tangible value. “By integrating Hippocratic AI’s secure, clinical-grade agents with BCG’s strategy and governance frameworks, we can help clients build trusted, scalable AI systems that deliver real impact.” Munjal Shah, Founder and CEO of Hippocratic AI, emphasized the shared mission of improving patient outcomes. “Our collaboration with BCG is rooted in a commitment to safe, ethical, and effective AI. By combining our technology with BCG’s strategic and operational leadership, we can bring scalable, empathetic, and clinically aligned support to patients, providers, and researchers worldwide.” Hippocratic AI has raised $404 million to date from top-tier investors including Andreessen Horowitz, General Catalyst, Kleiner Perkins, Avenir, NVIDIA’s NVentures, Premji Invest, SV Angel, and CapitalG. The company partners with more than 50 health systems, payers, and life sciences organizations globally. BCG, founded in 1963, is a global leader in management consulting, technology, and digital ventures. The firm partners with organizations to drive transformation, create sustainable advantage, and deliver positive societal impact. Learn more at www.bcg.com.